Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC
Dr Christina Baik - University of Washington School of Medicine, Seattle, USA
Patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated NSCLC ( Dr Christina Baik - University of Washington School of Medicine, Seattle, USA )
11 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 1
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve...
Dr Joshua Sabari and Dr Anna Minchom
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )
8 Jun 2021
Clinical trials participation is directly influenced by the information received...
Dr Daniel Vorobiof - Belong.Life, New York, USA
Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )
4 Jun 2021
mCRPC: Latest developments in diagnostics and combination therapies
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor
mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )
4 Jun 2021
ASCO 2021: Renal cancer roundup
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
ASCO 2021: Renal cancer roundup ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2021
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
4 Jun 2021
European Cancer Organisation - Time to Act
Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands
European Cancer Organisation - Time to Act ( Dr Mirjam Crul - Amsterdam University Medical Center, Amsterdam, Netherlands )
19 May 2021